dose escalation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
FAD can be reduced to FADH2 through the addition of 2 H+ and 2 e−. FADH2 can also be oxidized by the loss of 1 H+ and 1 e− to form FADH. The FAD form can be recreated through the further loss of 1 H+ and 1 e−. FAD formation can also occur through the reduction and dehydration of flavin-N(5)-oxide. Based on the oxidation state, flavins take specific colors when in aqueous solution. Flavin-N(5)-oxide (super oxidized) is yellow-orange, FAD (fully oxidized) is yellow, FADH (half reduced) is either blue or red based on the pH, and the fully reduced form is colorless. Changing the form can have a large impact on other chemical properties. For example, FAD, the fully oxidized form is subject to nucleophilic attack, the fully reduced form, FADH2 has high polarizability, while the half reduced form is unstable in aqueous solution. FAD is an aromatic ring system, whereas FADH2 is not. This means that FADH2 is significantly higher in energy, without the stabilization through resonance that the aromatic structure provides. FADH2 is an energy-carrying molecule, because, once oxidized it regains aromaticity and releases the energy represented by this stabilization. The spectroscopic properties of FAD and its variants allows for reaction monitoring by use of UV-VIS absorption and fluorescence spectroscopies. Each form of FAD has distinct absorbance spectra, making for easy observation of changes in oxidation state. A major local absorbance maximum for FAD is observed at 450 nm, with an extinction coefficient of 11,300 M−1 cm−1.
In the late 1970s, it was shown that there is a single stranded covalently closed, i.e. circular form of RNA expressed throughout the animal and plant kingdom (see circRNA). circRNAs are thought to arise via a "back-splice" reaction where the spliceosome joins a upstream 3' acceptor to a downstream 5' donor splice site. So far the function of circRNAs is largely unknown, although for few examples a microRNA sponging activity has been demonstrated.
The First World War occurred from 1914 to 1918. In terms of human technological history, the scale of World War I was enabled by the technological advances of the Second Industrial Revolution and the resulting globalization that allowed global power projection and mass production of military hardware. It had been recognized that the complex system of opposing military alliances (the German and Austro-Hungarian Empires against the British, Italian, Russian, and French Empires) was likely, if war broke out, to lead to a worldwide conflict. That caused a very minute conflict between two countries to have the potential to set off a domino effect of alliances, triggering a world war. The fact that the powers involved had large overseas empires virtually guaranteed that such a war would be worldwide, as the colonies' resources would be a crucial strategic factor. The same strategic considerations also ensured that the combatants would strike at each other's colonies, thus spreading the wars far more widely than those of pre-Columbian times. War crimes were perpetrated in World War I. Chemical weapons were used in the war despite the Hague Conventions of 1899 and 1907 having outlawed the use of such weapons in warfare. The Ottoman Empire was responsible for the Armenian genocide, during the First World War, as well as other war crimes.
Sources: en.wikipedia.org
=== Collectors' Mug and free floats === The first time A&W Restaurants offered a day of free root beer floats was in 2004; under the old management, it was held on June 20, the date of A&W's anniversary, though it is unknown if it donated the proceeds, unlike the current administration. Mid-year, A&W announces the following year's Collectors' Mug, which has a single design for each year. In 2005, it had a full-color image of The Great Root Bear printed on it. By 2010, the event had changed to August 6. It was the chain's first attempt at a digital promotion, where users who liked its Facebook page would receive a digital coupon to redeem a free float. A&W supports Disabled American Veterans and, since 2013, collects funds for it on National Root Beer Float Day, which is observed on August 6. Donation figures for 2019 were of a record $175,000. In the 2000s it was held in June and was known as National Float Day.
After optimizing the concentration of graphene oxide concentration and anisotropic porous structure, tensile tests were performed. It was found that MGCA could recover 99.8% and 96.3% when compressed to 60% and 90% strain, respectively. SEM images showed that due to its unique structure, MCGA pore walls were able to wrinkle and fold during compression. Another unique characteristic of this material is its absorption capacity of 80-197 times its weight towards hydrophobic compounds, such as oils and chemical solvents. On the contrary, less effort has been made to study the stretchability of porous carbons. Gao, et al. synthesized a long-range lamellar scaffold composed of chitosan and graphene oxide via bidirectional freezing, freeze drying, and annealing. The result is a material with density of 11 mg cm−3 and porosity of about 99.4%. Various tensile tests were conducted, and it was found that carbon spring could revert to its original shape upon 80% compression strain and -60% stretching strain with a Poisson's ratio between 0.05 and 0.1. The narrow hysteresis loop of the stress-strain curve indicates a low energy dissipation (energy loss coefficient of about 0.2) because of its negligible interior friction, localized buckling, or cracks during deformation processes. The stretchable mechanical properties of this material allow for great candidates for vibrational and magnetism sensors.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
Sources: en.wikipedia.org
==== Officer of the Order of the British Empire (OBE) ==== Military Commander Trefor Morgan Fox, Royal Navy, C037045S. Commander Christopher Robert Hollingworth, Royal Navy, C041543F. Colonel Andrew Glenn David Lock, Royal Marines, N029023U. Commander Lucy Jane Ottley, Royal Navy, V030919T. Commander Ian Hayden Richardson, Royal Navy, C038366T. Commander Jamie Duncan Wells, Royal Navy, C039514F. Captain Allan Thomas Youp, Royal Navy, C038889U. Lieutenant Colonel Nicholas Paul Andrew, Royal Regiment of Artillery, 537949. Lieutenant Colonel Tracy-Louise Appleyard, Royal Army Medical Corps, 540495. Colonel Edward Hugh James Carter, 532335. Lieutenant Colonel Ewan Christian Noble Harris, The Royal Welsh, 545550. Lieutenant Colonel Timothy Matthew Holmes, Corps of Royal Electrical and Mechanical Engineers, 546527. Colonel Matthew Gordon Timothy Lewis, 554319. Lieutenant Colonel (now Acting Colonel) John Andrew Lyons, Royal Corps of Signals, 549561. Lieutenant Colonel Craig David Pope, Royal Army Medical Corps, 549180. Colonel Nigel Offley Crewe-Read, , 545207. Colonel Thomas Woolley, 551152. Colonel Nicholas George Charles Yardley, 544447. Wing Commander Erica Jane Ferguson, Royal Air Force, 2629012K. Wing Commander Matthew Elfed Lewis, Royal Air Force, 5208143G. Wing Commander Stephen McCleery, Royal Air Force, 2635078L. Wing Commander Alison Morton, Royal Air Force, W996632T. Air Commodore Patrick James Shea-Simonds, Royal Air Force, 5208323H. Group Captain Paul Andrew Weaver Smith, Royal Air Force, 8024057B.
Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study. However, PSPs hold large potential for translating degradomics into clinical applications, as once a PSP is established it could aid in quantifying proteolytic signature biomarkers in Single Reaction Monitoring (SRM) and Multiple Reaction Monitoring (MRM) type clinical assays.
In the 1990s, the groups that continued to research cold fusion and their supporters established (non-peer-reviewed) periodicals such as Fusion Facts, Cold Fusion Magazine, Infinite Energy Magazine and New Energy Times to cover developments in cold fusion and other fringe claims in energy production that were ignored in other venues. The internet has also become a major means of communication and self-publication for CF researchers.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。